---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-105027"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T07:10:59.446552+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics GSBR-1290 Phase 1b shows 4.9% weight loss but Phase 2a obesity data delayed to H1 2024

## Summary
- Phase 1b MAD: placebo-adjusted weight loss up to 4.9% at day 28; no severe AEs or discontinuations.
- Phase 2a obesity cohort data collection omission: 24 of 40 patients missing week 12 weight; new enrollment; topline now H1 2024.
- Phase 2a type 2 diabetes cohort topline still on track for latter half Q4 2023.
- Phase 2b studies (T2D ~500 pts, obesity ~275 pts) planned for 2024; formulation bridging study to tablets underway.
- GSBR-1290 generally well-tolerated; most AEs mild GI events; no clinically meaningful liver function changes.

## SEC filing metadata
- accession: 0001104659-23-105027
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923105027/0001104659-23-105027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923105027/tm2327162d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-105027
- JSON: https://secwatch.observer/filing/0001104659-23-105027.json
- Plain text: https://secwatch.observer/filing/0001104659-23-105027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.